Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on October 15, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print October 15, 2009, doi: 10.1161/ATVBAHA.109.196550
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van Himbergen, T. M.
Right arrow Articles by Stalenhoef, A. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Himbergen, T. M.
Right arrow Articles by Stalenhoef, A. F.

Submitted on May 20, 2009
Accepted on September 29, 2009

Familial Combined Hyperlipidemia Is Associated With Alterations in the Cholesterol Synthesis Pathway

Thomas M. van Himbergen *; Seiko Otokozawa ; Nirupa R. Matthan ; Ernst J. Schaefer ; Aaron Buchsbaum ; Masumi Ai ; Lambertus J.H. van Tits ; Jacqueline de Graaf ; and Anton F. Stalenhoef

From the Lipid Metabolism (T.M.v.H., S.O., E.J.S., A.B., M.A.) and Cardiovascular Nutrition Laboratories (N.R.M.), Human Nutrition Research Center on Aging at Tufts University, Boston, Mass; and the Department of General Internal Medicine (L.J.H.v.T., J.d.G., A.F.S.), Radboud University Nijmegen Medical Center, The Netherlands.

* To whom correspondence should be addressed. E-mail: thomas.vanhimbergen{at}tufts.edu.

Objectives—Familial combined hyperlipidemia (FCH) is a common familial lipid disorder characterized by increases in plasma total cholesterol, triglyceride, and apolipoprotein B-100 levels. In light of prior metabolic and genetic research, our purpose was to ascertain whether FCH cases had significant abnormalities of plasma markers of cholesterol synthesis and absorption as compared to unaffected kindred members.

Methods and Results—Plasma levels of squalene, desmosterol, and lathosterol (cholesterol synthesis markers) and campesterol, sitosterol, and cholestanol (cholesterol absorption markers) were measured by gas-liquid chromatography in 103 FCH patients and 240 normolipidemic relatives (NLR). Squalene, desmosterol, and lathosterol levels were 6% (0.078), 31%, (P<0.001) and 51% (P<0.001) higher in FCH as compared to NLR, and these differences were especially pronounced in women. An interaction with obesity was also noted for a subset of these markers. We did not observe any apparent differences for the cholesterol absorption markers among FCH patients and NLR.

Conclusions—Our data indicate that both men and women with FCH have alterations in the cholesterol synthesis pathway, resulting in 51% higher levels of lathosterol (and additionally desmosterol in women). Plasma levels of the cholesterol precursor sterol squalene were only slightly increased (6%), suggesting enhanced conversion of squalene to lathosterol in this disorder.


Key words: cholesterol • lipids • sterols • familial combined hyperlipidemia